Urology
Volume 75, Issue 4 , Pages 762-767 , April 2010

ERG Rearrangement Metastasis Patterns in Locally Advanced Prostate Cancer

  • Sven Perner

      Affiliations

    • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
    • ,
  • Maria A. Svensson

      Affiliations

    • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
    • Department of Laboratory Medicine, University Hospital of Örebro, Örebro, Sweden
    • ,
  • Ruhella R. Hossain

      Affiliations

    • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
    • ,
  • John R. Day

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • ,
  • Jack Groskopf

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • ,
  • Ryan C. Slaughter

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • ,
  • Analee R. Jarleborn

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • ,
  • Matthias D. Hofer

      Affiliations

    • Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Rainer Kuefer

      Affiliations

    • Department of Urology, University Hospital of Ulm, Ulm, Germany
    • ,
  • Francesca Demichelis

      Affiliations

    • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
    • Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York
    • ,
  • David S. Rickman

      Affiliations

    • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
    • ,
  • Mark A. Rubin

      Affiliations

    • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
    • Corresponding Author InformationReprint requests: Mark A. Rubin, M.D., Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, 1300 York Avenue Room C 410-A, New York, NY 10065

Received 24 May 2009 ,Accepted 4 October 2009.

References 

  1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648
  2. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882–888
  3. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20:538–544
  4. Hermans KG, van Marion R, van Dekken H, et al. TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006;66:10658–10663
  5. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396–3400
  6. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008;68:7629–7637
  7. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596–4599
  8. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27:253–263
  9. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69:1400–1406
  10. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008;68:3584–3590
  11. Greene DR, Wheeler TM, Egawa S, et al. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol. 1991;146:1069–1076
  12. Ruijter ET, van de Kaa CA, Schalken JA, et al. Histological grade heterogeneity in multifocal prostate cancer (Biological and clinical implications). J Pathol. 1996;180:295–299
  13. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004;100:2362–2366
  14. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007;67:7991–7995
  15. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene. 2008;27:1993–2003
  16. Barry M, Perner S, Demichelis F, et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology. 2007;70:630–633
  17. Hofer MD, Kuefer R, Huang W, et al. Prognostic factors in lymph node-positive prostate cancer. Urology. 2006;67:1016–1021
  18. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst. 1998;90:233–237
  19. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66:8337–8341
  20. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100:815–825
  21. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089–1095
  22. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006;66:8347–8351
  23. Pflueger D, Rickman DS, Sboner A, et al. Transcriptome sequencing identifies NDRG1-ERG fusion prostate cancer. Neoplasia. 2009;11:804–811
  24. Paris PL, Hofer MD, Albo G, et al. Genomic profiling of hormone-naive lymph node metastases in patients with prostate cancer. Neoplasia. 2006;8:1083–1089
  25. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA. 2008;105:2105–2110
  26. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10:177–188
  27. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41:619–624
  28. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41:524–526
  29. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69:2912–2918
  30. Rubin MA, Gerstein A, Reid K, et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol. 2000;31:504–508
  31. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68:645–649

 Supported by the Department of Defense Grant to S.P. (PC61474) and NCI Grant to F.D. and M.A.R. (R01CA125612).

 Sven Perner and Maria A. Svensson have contributed equally for the preparation of this manuscript.

PII: S0090-4295(09)02721-6

doi: 10.1016/j.urology.2009.10.010

Urology
Volume 75, Issue 4 , Pages 762-767 , April 2010

Article Tools

* Image Usage & Resolution